The United States immunology drugs report provides market analysis, sizing, forecasts, dosage units sold, average selling prices, and market shares of the immunology drugs within 5 major diseases. The report analyses key factors instrumental in changing the market scenario and provides a forecast of the future immunology market in the United States. Key market players are profiled and a detailed view of their current strategic interests and a review on their financial performance has been provided.

The global markets as defined in the reports include the United States, Europe (EU5 – The United Kingdom, Spain, Italy, Germany, France and others), and Rest of World (Brazil, Russia, India, China, Japan, and Canada).

The Europe immunology drugs report provides market analysis, sizing, forecasts, and market shares of the immunology drugs. The report analyses key factors instrumental in changing the market scenario and provide a forecast of the future immunology market across the major 5 countries in Europe. Key market players are profiled and a detailed view of their current strategic interests and a review on their financial performance has been provided.

The Japan and BRIC immunology drugs report provides market analysis, sizing, forecasts, and market shares of the immunology drugs. The report analyses key factors instrumental in changing the market scenario and provide a forecast of the future immunology market in Brazil, Russia, India and China. Key market players are profiled and a detailed view of their current strategic interests and a review on their financial performance has been provided.

This market report includes a detailed analysis of the drugs used to treat ulcerative colitis in Europe, including Entyvio, Humira, Remicade, and Simponi. The ulcerative colitis drug market is largely driven by the expiry of patents and the entry of biosimilars which present strong competition for the biologics listed above.

The Europe immunology market includes biologic drugs that are used in the treatment of various immunology diseases such as rheumatoid arthritis (RA), ankylosing spondylitis (AS), Crohn`s disease (CD), ulcerative colitis (UC) and psoriasis (PsO). As there is a need for cost effective drugs in treating these diseases, there is an increased number of drugs in development for these diseases. Current treatment mainly constitutes NSAIDs and biologics.

This market report includes a detailed analysis of the drugs used to treat ulcerative colitis across the globe (12 countries), including Entyvio, Humira, Remicade, and Simponi. The ulcerative colitis drug market is largely driven by the expiry of patents and the entry of biosimilars which present strong competition for the biologics listed above.

This market report includes a detailed analysis of the drugs used to treat psoriasis across the globe (12 countries), including Humira, Enbrel, Remicade, and Stelera. The psoriasis drug market is largely driven by the expiry of patents and the entry of biosimilars which present strong competition for the biologics listed above.

This market report includes a detailed analysis of the drugs used to treat rheumatoid arthritis across the globe (12 countries), including Orencia, Humira, Cimzia, Enbrel, Simponi, Remicade, Rituxan, Actemra, and Xeljanz. The rheumatoid arthritis drug market is largely driven by the expiry of patents and the entry of biosimilars which present strong competition for the biologics listed above.

This market report includes a detailed analysis of the drugs used to treat ankylosing spondylitis across the globe (12 countries), including Humira, Cimzia, Enbrel, Simponi, and Remicade. The ankylosing spondylitis drug market is largely driven by the expiry of patents and the entry of biosimilars which present strong competition for the biologics listed above.

This market report includes a detailed analysis of the drugs used to treat Crohn's disease across the globe (12 countries), including Humira, Cimzia, Remicade, Stelara, Entyvio, and Tysabri. The Crohn's disease drug market is largely driven by the expiry of patents and the entry of biosimilars which present strong competition for the biologics listed above.

This market report includes a detailed analysis of the drugs used to treat ulcerative colitis outside the U.S. and Europe, including Entyvio, Humira, Remicade, and Simponi. The ulcerative colitis drug market is largely driven by the expiry of patents and the entry of biosimilars which present strong competition for the biologics listed above.

This market report includes a detailed analysis of the drugs used to treat psoriasis outside the U.S. and Europe, including Humira, Enbrel, Remicade, and Stelera. The psoriasis drug market is largely driven by the expiry of patents and the entry of biosimilars which present strong competition for the biologics listed above.

This market report includes a detailed analysis of the drugs used to treat rheumatoid arthritis outside the U.S. and Europe, including Orencia, Humira, Cimzia, Enbrel, Simponi, Remicade, Rituxan, Actemra, and Xeljanz. The rheumatoid arthritis drug market is largely driven by the expiry of patents and the entry of biosimilars which present strong competition for the biologics listed above.

This market report includes a detailed analysis of the drugs used to treat ankylosing spondylitis outside the U.S. and Europe, including Humira, Cimzia, Enbrel, Simponi, and Remicade. The ankylosing spondylitis drug market is largely driven by the expiry of patents and the entry of biosimilars which present strong competition for the biologics listed above.

This market report includes a detailed analysis of the drugs used to treat Crohn’s disease outside the U.S. and Europe, including Humira, Cimzia, Remicade, Stelara, Entyvio, and Tysabri. The Crohn’s disease drug market is largely driven by the expiry of patents and the entry of biosimilars which present strong competition for the biologics listed above.